DJ Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc.
The Vanguard Group, Inc. ( IRSH) Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc. 17-Sep-2021 / 13:13 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
Ap19
FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION
Name of person dealing (Note 1) The Vanguard Group, Inc. Company dealt in Xeris Pharmaceuticals, Inc. Class of relevant security to which the dealings being disclosed relate (Note 2) USD0.001 Common Stock Date of dealing 15 September 2021
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long Short
Numbers (%) Numbers (%)
(1) Relevant securities 2,935,028 4.41%
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total 2,935,028 4.41%
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: Long Short
Numbers (%) Numbers (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
Ap20
1. Dealings (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5) Purchase 10,288 2.55 USD
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit e.g. CFD (Note 6) (Note 7) (Note 5) Not Applicable
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of securities to Type, e.g. Option money paid/
purchasing, varying which the option relates Exercise American, Expiry received per unit
e.g. call etc. (Note 7) price European etc. date (Note 5)
option
Not
Applicable
(ii) Exercising
Product name, Exercise price per unit (Note 5)
Number of securities
e.g. call option
Not Applicable
(e) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction Price per unit
Details
(Note 8) (if applicable) (Note 5)
Not Applicable
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 17 September 2021 Contact name Shawn Acker Telephone number 001-610-669-8989 If a connected EFM, name of offeree/offeror with which connected If a connected EFM, state nature of connection (Note 10)
-----------------------------------------------------------------------------------------------------------------------
Category Code: RET - Xeris Pharmaceuticals, Inc. TIDM: IRSH LEI Code: 5493002789CX3L0CJP65 Sequence No.: 122452 EQS News ID: 1234288 End of Announcement EQS News Service =------------------------------------------------------------------------------------
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1234288&application_name=news
(END) Dow Jones Newswires
September 17, 2021 08:13 ET (12:13 GMT)
